In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.01651-07PMID 18443106PMCID PMC2443883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small Colony Variants: a Pathogenic Form of Bacteria that Facilitates Persistent and Recurrent Infections

  2009influential reference
• In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus

  2008influential reference
• Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs.

  2008cited by this paper
• Quinolone-Mediated Bacterial Death

  2007influential reference
• Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

  2007cited by this paper
• Efflux-Related Resistance to Norfloxacin, Dyes, and Biocides in Bloodstream Isolates of Staphylococcus aureus

  2007cited by this paper
• A global view of Staphylococcus aureus whole genome expression upon internalization in human epithelial cells

  2007cited by this paper
• Methicillin-resistant S. aureus infections among patients in the emergency department.

  2006cited by this paper
• Allelic replacement in Staphylococcus aureus with inducible counter-selection.

  2006cited by this paper
• Intracellular residency is frequently associated with recurrent Staphylococcus aureus rhinosinusitis.

  2006cited by this paper
• Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections

  2006cited by this paper
• Deletion of the Multiple-Drug Efflux Pump AcrAB in Escherichiacoli Prolongs the Postantibiotic Effect

  2005cited by this paper
• Lethality of Quinolones against Mycobacterium smegmatis in the Presence or Absence of Chloramphenicol

  2005cited by this paper
• Correction

  2004cited by this paper
• Effect of Disruption of Staphylococcus aureus PBP4 Gene on Resistance to β-Lactam Antibiotics

  2003cited by this paper
• The mutant selection window and antimicrobial resistance.

  2003cited by this paper
• Fluoroquinolones: action and resistance.

  2003cited by this paper
• Mechanisms of Quinolone Action

  2003cited by this paper
• Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus.

  2002cited by this paper
• Increased Expression of Clumping Factor and Fibronectin-Binding Proteins by hemB Mutants of Staphylococcus aureus Expressing Small Colony Variant Phenotypes

  2002cited by this paper
• Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

  2002cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Mechanism of quinolone resistance in Staphylococcus aureus

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.

  1999cited by this paper
• Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains ofStaphylococcus aureus

  1999cited by this paper
• The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.

  1998cited by this paper
• A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly

  1997cited by this paper

• Strategic re-engineering of antibiotics

  2024cites this paper
• In Silico Study of the Potential Inhibitory Effects on Escherichia coli DNA Gyrase of Some Hypothetical Fluoroquinolone–Tetracycline Hybrids

  2024cites this paper
• Macrocyclic-based strategy in drug design: From lab to the clinic.

  2024cites this paper
• An Update on the Clinical Pipelines of New Antibacterial Drugs Developed in China

  2024cites this paper
• Metabolomics in drug discovery: Restoring antibiotic pipeline

  2023cites this paper
• Antibiotics in the clinical pipeline as of December 2022

  2023cites this paper
• Drug Combinations to Prevent Antimicrobial Resistance: Various Correlations and Laws, and Their Verifications, Thus Proposing Some Principles and a Preliminary Scheme

  2022cites this paper
• Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance

  2022cites this paper
• Metabolomics in antimicrobial drug discovery

  2022cites this paper
• Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

  2022cites this paper
• Magic bullets, magic shields, and antimicrobials in between

  2022cites this paper
• Fresh Molecular Concepts to Extend the Lifetimes of Old Antimicrobial Drugs

  2021cites this paper
• Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.

  2021cites this paper
• Formulas Estimating Glomerular Filtration Rate in the Evaluation of Living Kidney Donor Candidates: Comparison of Different Formulas With Scintigraphy-Measured Glomerular Filtration Rate.

  2020cites this paper
• In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci.

  2020cites this paper
• Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials

  2020cites this paper
• Antibiotics in the clinical pipeline in October 2019

  2020cites this paper
• The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance

  2020cites this paper
• Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids

  2019cites this paper
• Recent advances in the synthetic and medicinal perspective of quinolones: A review.

  2019cites this paper
• Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules

  2018cites this paper
• Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

  2018cites this paper
• Synergistic combination of two antimicrobial agents closing each other’s mutant selection windows to prevent antimicrobial resistance

  2018cites this paper
• Recent developments of quinolone-based derivatives and their activities against Escherichia coli.

  2018cites this paper
• Covalently linked kanamycin - Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance.

  2017cites this paper
• Bifunctional antimicrobial conjugates and hybrid antimicrobials.

  2017cites this paper
• Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.

  2016cites this paper
• A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.

  2016influential citation
• Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study

  2016cites this paper
• Mutant Selection Windows of Azalomycin F 5a in Combination with Vitamin K 3 against Methicillin-Resistant Staphylococcus aureus

  2016cites this paper
• Hybrid antibiotics – clinical progress and novel designs

  2016cites this paper
• Design of dual action antibiotics as an approach to search for new promising drugs

  2015cites this paper
• Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.

  2014cites this paper
• Design, Synthesis, and Antibacterial Properties of Dual-Ligand Inhibitors of Acetyl-CoA Carboxylase and Mechanism of Action for the Antibacterial Agent Moiramide B

  2014cites this paper
• Importancia de la producción de biopelícula en infecciones protésicas causadas por Staphylococcus sp.: Implicaciones terapeúticas

  2014cites this paper
• Die Bekämpfung multiresistenter Bakterien: aktuelle Strategien zur Entdeckung neuer Antibiotika

  2013cites this paper
• Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.

  2013cites this paper
• Tuberculosis: laboratory diagnosis and treatment strategies.

  2013cites this paper
• Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.

  2013cites this paper
• Recent derivatives from smaller classes of fermentation-derived antibacterials

  2012cites this paper
• Natural products: an evolving role in future drug discovery.

  2011cites this paper
• Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success.

  2011cites this paper
• Rifaximin intake leads to emergence of rifampin-resistant staphylococci.

  2011cites this paper
• Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment

  2011cites this paper
• Purification and identification of antibacterial phenolics from Tripodanthus acutifolius leaves

  2010cites this paper
• New quinolone antibiotics: a survey of the literature from 2005 to 2010

  2010cites this paper
• An overview of conventional and alternative strategies for developing new antibacterial agents.

  2010cites this paper
• Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance

  2010cites this paper
• Rifamycins e Obstacles and opportunities

  2010cites this paper
• Rifamycins--obstacles and opportunities.

  2010cites this paper
• Newer antibacterial drugs for a new century

  2010cites this paper
• Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation.

  2009cites this paper
• Novel heterodimer antibiotics: a review of recent patent literature.

  2009cites this paper
• Quinolones: Action and Resistance Updated

  2009cites this paper
• In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus

  2008influential citation
• How many modes of action should an antibiotic have?

  2008cites this paper
• Recent Advances in the Discovery of Hybrid Antibacterial Agents

  2008cites this paper